Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) (STEC-HUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01410916
Recruitment Status : Completed
First Posted : August 5, 2011
Last Update Posted : April 5, 2013
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
This protocol is designed to collect safety and efficacy data on patients that have been or will be treated with eculizumab for STEC-HUS, in the context of the 2011 STEC-HUS epidemic in Germany.

Condition or disease Intervention/treatment Phase
Shiga-like Toxin-producing Escherichia Coli Drug: Eculizumab (Soliris®) Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 198 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-Center Trial of Eculizumab in Patients With Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)
Study Start Date : July 2011
Actual Primary Completion Date : January 2012
Actual Study Completion Date : June 2012

Intervention Details:
    Drug: Eculizumab (Soliris®)
    Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously

Primary Outcome Measures :
  1. Improvement in Systemic TMA & Vital Organ Involvement at 8 weeks of treatment defined as either complete or partial responder based on hematologic normalization/improvement & clinically important improvement in Vital Organs: Brain, Kidney, and Thrombosis [ Time Frame: 8 weeks ]
    Analysis of primary endpoint will occur after all patients have reached 8 weeks of treatment. The response rate will be summarized as patients who are either a complete or partial responder.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Months and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient must be willing and able to give written informed consent/Assent.
  2. Adults, adolescents, or pediatric (≥2 months and ≥5kg) patients
  3. Patient has been diagnosed with Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)

Exclusion Criteria:

  1. Known complement regulatory mutation or family history of complement regulatory mutation
  2. Unresolved systemic meningococcal disease
  3. 3. Hypersensitivity to eculizumab, to murine proteins or to one of the excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01410916

Bielefeld, Germany, 33615
Bielefeld, Germany, 33617
Bonn, Germany, 53127
Bremen, Germany, 28177
Bremerhaven, Germany, 27574
Essen, Germany, 45147
Flensburg, Germany, 24939
Göttingen, Germany, 37075
Hamburg, Germany, 20246
Hamburg, Germany, 22291
Hamburg, Germany, 22359
Hannover, Germany, 30625
Karlsruhe, Germany, 76133
Köln, Germany, 50937
Lubeck, Germany, 23538
Magdeburg, Germany, 39120
Munchen, Germany, 81377
Munich, Germany, 80804
Munster, Germany, 48149
Oldenburg, Germany, 26133
Ulm, Germany, 89081
Wildeshausen, Germany, 27793
Sponsors and Collaborators
Alexion Pharmaceuticals

Responsible Party: Alexion Pharmaceuticals Identifier: NCT01410916     History of Changes
Other Study ID Numbers: C11-001
2011-002691-17 ( EudraCT Number )
First Posted: August 5, 2011    Key Record Dates
Last Update Posted: April 5, 2013
Last Verified: April 2013

Keywords provided by Alexion Pharmaceuticals:
Shiga-like toxin-producing Escherichia Coli Hemolytic-Uremic Syndrome
uncontrolled complement activation

Additional relevant MeSH terms:
Hemolytic-Uremic Syndrome
Pathologic Processes
Kidney Diseases
Urologic Diseases
Anemia, Hemolytic
Hematologic Diseases
Thrombotic Microangiopathies
Blood Platelet Disorders
Shiga Toxins
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action